Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changfu versus Baxter peritoneal dialysate in CAPD for end-stage renal disease
ChiCTR-TRC-10001008Phase 4Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Changfu peritoneal dialysate and peritoneal dialysis solution in end-stage kidney disease (ESKD) (4 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Change in Kt/V from baseline and Change in Ccr from baseline. Started Oct 2010; status: completed.
02
Drugs
Changfu peritoneal dialysateperitoneal dialysis solution
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR-TRC-10001008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001008.